ACCOUNTS - Final Accounts preparation

ACCOUNTS - Final Accounts preparation

AMYNEPHARMA LIMITED - Company Information

Print Friendly Version

07798764 AMYNEPHARMA LIMITED 2014-11-01 2015-10-31 false true 2015-10-31true 07798764 c:EntityAccountantsOrAuditors 2015-10-31 07798764 2014-11-01 2015-10-31 07798764 2015-10-31 07798764 2014-10-31 07798764 c:OrdinaryShareClass1 2015-10-31 07798764 c:OrdinaryShareClass1 2014-10-31 07798764 c:OrdinaryShareClass1 2014-11-01 2015-10-31 07798764 c:Director1 2014-11-01 2015-10-31 07798764 d:ComputerEquipment 2014-11-01 2015-10-31 07798764 c:EntityAccountantsOrAuditors 2014-11-01 2015-10-31 xbrli:shares iso4217:GBP

Registered number: 07798764








AMYNEPHARMA LIMITED







UNAUDITED

ABBREVIATED ACCOUNTS

FOR THE YEAR ENDED 31 OCTOBER 2015































BAGINSKY COHEN

CHARTERED ACCOUNTANTS
 
AMYNEPHARMA LIMITED
 
 
The following reproduces the text of the Chartered accountants' report in respect of the company's annual financial statements, from which the abbreviated accounts (set out on pages 2 to 4) have been prepared.
  
CHARTERED ACCOUNTANTS' REPORT TO THE DIRECTOR ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF AMYNEPHARMA LIMITED
FOR THE YEAR ENDED 31 OCTOBER 2015

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Amynepharma Limited for the year ended 31 October 2015 which comprise the Profit and loss account, the Balance sheet and the related notes from the company's accounting records and from information and explanations you have given to us.
 

As a member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at icaew.com/regulations.


This report is made solely to the director of Amynepharma Limited in accordance with the terms of our engagement letter dated 6 October 2011. Our work has been undertaken solely to prepare for your approval the financial statements of Amynepharma Limited and state those matters that we have agreed to state to the director of Amynepharma Limited in this report in accordance with AAF 2/10 as detailed at icaew.com/compilation. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Amynepharma Limited and its director for our work or for this report.
 
 
It is your duty to ensure that Amynepharma Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the company's assets, liabilities, financial position and profit. You consider that Amynepharma Limited is exempt from the statutory audit requirement for the year.
 
 
We have not been instructed to carry out an audit or review of the financial statements of Amynepharma Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.





BAGINSKY COHEN
CHARTERED ACCOUNTANTS
930 HIGH ROAD
LONDON
N12 9RT

12 February 2016
Page 1
 
AMYNEPHARMA LIMITED
REGISTERED NUMBER: 07798764

ABBREVIATED BALANCE SHEET
AS AT 31 OCTOBER 2015

2015
2014
Note
£
£
£
£
 
FIXED ASSETS





 
Tangible assets
 
2
1,667
2,031
 
CURRENT ASSETS





 
Debtors
170
126

 
Cash at bank

325,985
348,563







 
326,155
348,689
 
CREDITORS: amounts falling due within one year
(27,271)
(45,876)
 
NET CURRENT ASSETS


298,884

302,813
 
TOTAL ASSETS LESS CURRENT LIABILITIES
 300,551

 304,844
  
CAPITAL AND RESERVES

 
Called up share capital
3
100
100
 
Profit and loss account
300,451
304,744
 
SHAREHOLDERS' FUNDS
 

 300,551

 304,844


The director considers that the company is entitled to exemption from the requirement to have an audit under the provisions of section 477 of the Companies Act 2006 ("the Act") and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Act. 

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The abbreviated accounts, which have been prepared in accordance with the provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006, were approved and authorised for issue by the board and were signed on its behalf on 12 February 2016.





A HIOUNI
Director

The notes on pages 3 to 4 form part of these financial statements.

Page 2

 
AMYNEPHARMA LIMITED
 
 
NOTES TO THE ABBREVIATED ACCOUNTS
FOR THE YEAR ENDED 31 OCTOBER 2015

1.ACCOUNTING POLICIES

1.1
Basis of preparation of financial statements

The full financial statements, from which these abbreviated accounts have been extracted, have been prepared under the historical cost convention and in accordance with applicable accounting standards.

1.2
Cash flow

The company has taken advantage of the exemption in Financial Reporting Standard No.1 from the requirement to produce a cash flow statement on the grounds that it is a small company.

1.3
Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost less depreciation.  Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Computer equipment
-
25% reducing balance

1.4
Turnover

Turnover comprises revenue recognised by the company in respect of services supplied during the year.

1.5
Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the balance sheet date.
Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction.
Exchange gains and losses are recognised in the Profit and loss account.


2.TANGIBLE FIXED ASSETS



£


Cost 


At 1 November 2014
3,698

Additions
192


At 31 October 2015

3,890



Depreciation


At 1 November 2014
1,667

Charge for the year
556


At 31 October 2015

2,223




Net book value


At 31 October 2015
 1,667


At 31 October 2014

 2,031

Page 3

 
AMYNEPHARMA LIMITED
 
 
NOTES TO THE ABBREVIATED ACCOUNTS
FOR THE YEAR ENDED 31 OCTOBER 2015

3.SHARE CAPITAL
        2015
        2014
        £

        £

Allotted, called up and fully paid



100 Ordinary shares shares of £1 each
 100
 100

Page 4